Table 2 Univariate analysis of clinical and pathological factors of per-protocol population (n = 21)
Median PFS (95% CI) | p | Median OS (95% CI) | p | |
|---|---|---|---|---|
Age | 0.12 | 0.54 | ||
20–57 | 3.9 (1–6.7) | 11.9 (6.7–17.1) | ||
>57 | 5.7 (3.1–8.2) | 13.3 (6.1–20.3) | ||
Sex | 0.13 | 0.045 | ||
Male | 1.9 (0–5.6) | 9.4 (4.3–14.6) | ||
Female | 5.7 (4.4–6.9) | 15.5 (14.6–16.4) | ||
Histology | 0.18 | 0.072 | ||
Leiomyosarcoma | 5.7 (0–13.7) | 15.5 (14.7–16.3) | ||
Others | 3.9 (3.3–4.5) | 10.6 (7- 14.1) | ||
ECOG | 0.89 | 0.014 | ||
0 | 4.2 (2.1–6.2) | 21.9 (10.8–33.1) | ||
1 | 1.9 (0–5.1) | 10.6 (0–22) | ||
Extension at diagnosis | 0.44 | 0.96 | ||
Localized | 4.3 (0.7–7.9) | 11.9 (10–13.7) | ||
Locally advanced | 3.9 (0.4–7.3) | 16.7 (0–45.4) | ||
Metastatic | 1 (0–5.6) | 2.3 (0–14.1) | ||
Extension at baseline | 0.79 | 0.96 | ||
Locally advanced | 4.3 (NA) | 10.6 (NA) | ||
Metastatic | 3.9 (0.7–7.2) | 12 (9.6–14.5) | ||
Location | 0.51 | 0.65 | ||
Somatic | 4.3 (3.7–4.9) | 12 (5.5–18.5) | ||
Visceral | 1.9 (0.7–3.2) | 11.9 (0–27.1) | ||
Primary size | 0.58 | 0.43 | ||
0–99 | 5.2 (1.2–9.3) | 15.5 (13.4–17.6) | ||
>99 | 3.9 (0.5–7.4) | 10.6 (4.9–16.2) | ||
Best response | <0.001 | <0.001 | ||
SD | 5.9 (3.4–8.4) | 16.7 (11.7–21.6) | ||
PD | 1.1 (0.6–1.5) | 2.3 (0.9–3.7) |
